1 in 5 consumers chose foodservice delivery over dine-in in 2024: Euromonitor International
Asia Pacific contributes 40% of global foodservice sales.
Euromonitor International's World Market for Consumer Foodservice 2025 report highlights this is driven by robust growth in the Asia Pacific region, which contributed to 40% of global foodservice sales, with a 6% forecast value Compound Annual Growth Rate (CAGR) for 2029.
Despite economic uncertainties, the global consumer foodservice industry grew in 2024, reaching a total market value of USD3.2 trillion, a 5.5% increase from 2023. This indicates a continued path to recovery and growth opportunities.
Rocio Franco, senior consultant at Euromonitor International, said: 'Inflation and economic uncertainty remain major concerns for consumers. Despite global transactions recovering to pre-pandemic levels, indicating strong demand in the industry, consumers are still cutting back on spending and opting for more affordable options.'
Eat-in continues to lose share while delivery continues to grow
Delivery is increasingly taking market share from eat-in dining, making up 21% of the global consumer foodservice market in 2024, up from 9% in 2019.
By 2029, delivery is projected to account for 24% of the foodservice market by 2029, while eat-in is expected to lose its share by 3%, down to 52% by 2029. While high inflation has helped many markets bounce back to 2019 pre-pandemic levels, constant sales are forecast to only recover fully from 2026.
Offering convenience and value, third-party players have amplified this with aggressive discount competition and increased loyalty programme subscriptions, often removing delivery or service charges to enhance frequency in orders.
Limited-service restaurants are also experiencing a boom, appealing to cost-conscious diners as they offer a flexible range of products. By strategising on 'snackification' with options ranging from smaller-sized, budget-friendly products to more premium choices, this strikes a balance between value and quality for consumers.
Digital innovation and personalisation at the forefront
Foodservice brands have been leveraging technology to meet rising consumer expectations and differentiate in a crowded market. From launching proprietary apps to expanding loyalty programmes, this enables brands to hyper-personalise consumers' experiences by tailoring offerings and promotions based on individual needs.
Franco commented: 'To retain customers, restaurant operators must strategise to offer value beyond price, focusing on enhancing experiences, embracing digitalisation, and building brand loyalty.'
Innovations such as such as self-service kiosks, digital recognition, and voice automation in drive-throughs are helping enhance customer engagement, support new product development and provide a competitive edge while driving omnichannel growth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
28 minutes ago
- Associated Press
JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial
HYOGO, Japan--(BUSINESS WIRE)--Jul 2, 2025-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) announced that it achieved the enrollment of the target number of participants in the global Phase III clinical trial of JR-141 (INN: pabinafusp alfa), which is in development for the treatment of mucopolysaccharidosis type II (MPS II, also known as Hunter syndrome). The Phase III clinical trial is ongoing in the United States, Latin America, and Europe. ( JR-141-GS31 ) JR-141 is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in people with Hunter syndrome. JR-141 was developed using J-Brain Cargo ®, JCR's proprietary blood-brain barrier (BBB)-penetrating technology, which is designed to deliver biotherapeutics across the BBB into the central nervous system (CNS) to address the neurological symptoms of Hunter syndrome. 'This achievement is a milestone in the JR-141 clinical development program, as the Hunter syndrome community needs a therapy that treats the cognitive symptoms of this devastating and life-threatening disease for which there are inadequate treatment options available,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'We are making good progress in this global Phase III clinical trial, and we look forward to sharing the clinical data as they are available. Thank you to all the participants who are part of this clinical trial.' In March 2021, the Ministry of Health, Labour and Welfare (MHLW) in Japan approved JR-141 (also known by the brand name IZCARGO ® ) for a lysosomal storage disorder. JR-141 is the first-ever approved ERT in the world that penetrates the BBB. About JR-141 JR-141 (INN: pabinafusp alfa) is a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase, the enzyme that is missing or malfunctioning in subjects with Hunter syndrome. It incorporates J-Brain Cargo ®, JCR's proprietary blood-brain barrier (BBB)-penetrating technology, to cross the BBB through transferrin receptor-mediated transcytosis, and its uptake into cells is mediated through the mannose-6-phosphate receptor. This novel mechanism of action is expected to make JR-141 effective against the central nervous system (CNS) symptoms of Hunter syndrome. In non-clinical trials, JCR has confirmed both high-affinity binding of pabinafusp alfa to transferrin receptors and passage across the BBB into neuronal cells. In addition, JCR has confirmed enzyme uptake in various brain tissues. The company has also confirmed a reduction of substrate accumulation in the CNS and peripheral organs in an animal model of Hunter syndrome. 1,2 In several clinical trials of pabinafusp alfa, JCR obtained evidence of reducing heparan sulfate concentrations in the cerebrospinal fluid, a biomarker for assessing effectiveness against CNS symptoms; these results were consistent with those obtained in pre-clinical studies. 3 Clinical studies have also demonstrated the positive effects of pabinafusp alfa on CNS symptoms. 4,5,6 About Mucopolysaccharidosis Type II (Hunter Syndrome) Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex carbohydrates called glycosaminoglycans (GAGs, also known as mucopolysaccharides) in the body. Hunter syndrome, which affects an estimated 2,000-3,000 individuals worldwide (according to JCR research), gives rise to a wide range of somatic and neurological symptoms. The current standard of care for Hunter syndrome is enzyme replacement therapy. Central nervous system symptoms related to MPS II have been unmet medical needs so far. About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as 'believe,' 'estimate,' 'anticipate,' 'intend,' 'plan,' 'will,' 'would,' 'target' and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future. 2: Morimoto, et al. Clearance of heparin sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Mol. Ther. 2021; 29(5): 1853-1861. 3: Okuyama, et al. Iduronate-2-sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial. Mol Ther. 2020; 27(2): 456-464. 4: Okuyama, et al. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II. Mol Ther. 2021; 29(2): 671-679. 5: Giugliani, et al. Iduronate-2-sulfatase fused with anti-human transferrin receptor antibody, pabinafusp alfa, for treatment of neuronopathic and non-neuronopathic mucopolysaccharidosis II: Report of a phase 2 trial in Brazil. Mol Ther. 2021; 29(7): 2378-2386. 6: Giugliani, et al. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II; an Integrated Analysis of Preclinical and Clinical Data. Int. J. Mol. Sci. 2021, Volume 22, Issue 20, 10938. View source version on CONTACT: Investors & Media: JCR Pharmaceuticals Co., Ltd. Corporate Communications [email protected] KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC INDUSTRY KEYWORD: RESEARCH NEUROLOGY CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE SOURCE: JCR Pharmaceuticals Co., Ltd. Copyright Business Wire 2025. PUB: 07/02/2025 11:12 AM/DISC: 07/02/2025 11:12 AM
Associated Press
29 minutes ago
- Associated Press
$5.91 Billion Market is Scaling Through Platform Expansion, OEM Trade-In, and Circular Retail Enablements - Forecast to 2029
DUBLIN--(BUSINESS WIRE)--Jul 2, 2025-- The 'India Recommerce Market Intelligence Databook - 60+ KPIs, Market Size, Share & Forecast by Channel, Category & Consumer Segment - Q2 2025 Update' report has been added to offering. The recommerce market in India is on a promising trajectory, projected to grow by 11.7% annually, reaching USD 5.91 billion by 2025. From 2020 to 2024, the market witnessed a significant CAGR of 14.6%, and it is anticipated to maintain a positive growth rate of 9.8% from 2025 to 2029, ultimately expanding to USD 8.61 billion by 2029. This report provides a detailed data-centric analysis of the recommerce market in India, covering market opportunities and risks across consumer segments (peer-to-peer and business-led resale); product categories; sales channels; and resale formats. With over 60+ KPIs at the country level, this report provides a comprehensive understanding of recommerce market dynamics. It offers a comprehensive analysis of market dynamics in the recommerce market, segmented by recommerce channels (C2C, B2C, trade-in programs), sales models (resale, rental, refurbishment), platform types (generalist and vertical-specific), digital engagement (app, website, social media), and retail categories (electronics, apparel, home goods, and more). In addition, it provides a snapshot of consumer behaviour, device usage, payment preferences, and city-level penetration across Tier 1 to Tier 3 cities. Recommerce in India Is Scaling Through Platform Expansion, OEM Trade-In, and Circular Retail Enablement India's recommerce sector is undergoing rapid expansion driven by mobile-led consumption, digital resale platforms, and retailer-OEM trade-in models. Consumer electronics remain the largest recommerce category, with fashion and furniture following. The segment is scaling through affordability, logistics reach, and emerging sustainability disclosures. Electronics Recommerce Is Expanding Through OEM Trade-In and Warranty-Backed Resale Fashion Recommerce Is Scaling via Platform Partnerships and Social Commerce Retailers Are Embedding Recommerce into Storefront Take-Back and Reverse Logistics Platform Recommerce Is Becoming Verticalized and Financially Enabled ESG Mandates and E-Waste Policies Are Enabling Circular Economy Channels Company Coverage: Report Scope India Recommerce Market Size and Growth Dynamics India Recommerce Market Size and Forecast by Sector India Recommerce Market Size and Forecast by Retail Category India Recommerce by Channel India Recommerce by Sales Model India Recommerce by Digital Engagement Channel India Recommerce by Platform Type India Recommerce by Device and OS India Recommerce by City Tier India Recommerce by Payment Instrument India Recommerce Market Share Analysis India Recommerce by Consumer Demographics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDIA ASIA PACIFIC INDUSTRY KEYWORD: FASHION SUPPLY CHAIN MANAGEMENT ONLINE RETAIL RETAIL CONSUMER ELECTRONICS TECHNOLOGY SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/02/2025 11:20 AM/DISC: 07/02/2025 11:20 AM
Yahoo
32 minutes ago
- Yahoo
LambdaTest Announces Deeper Collaboration with Appium as Strategic Partnership
Move to accelerate mobile test automation at scale with LambdaTest's expansive real device cloud, delivering unmatched accuracy, speed, and global reach. SAN FRANCISCO, July 02, 2025--(BUSINESS WIRE)--LambdaTest, a unified agentic AI and cloud engineering platform, has announced it has become a strategic sponsor of Appium, the world's most widely used open-source framework for mobile automation. This collaboration aims to significantly simplify and accelerate mobile test automation by integrating Appium's capabilities into LambdaTest's cloud-based distributed testing platform. LambdaTest has an active open-source program that provides access to LambdaTest's testing infrastructure to community projects, so maintainers can run comprehensive test suites without worrying about servers or setup. The organization had also launched LambdaTest Grants for Open Source to support innovation in software testing frameworks and toolsets. As part of the Grants, LambdaTest had announced a $250,000 grant for open source projects and contributors building solutions for the QA and Testing community. With this Appium Strategic Partnership, LambdaTest is doubling down on the commitment made to the open source community. Through this partnership, LambdaTest users will gain tighter integration and early access to improvements. Since Appium is at the heart of the LambdaTest platform, our contributions will allow the platform to incorporate updates and new capabilities faster than ever. This partnership also sets an example of how commercial platforms and open-source projects can join forces to uplift the entire tech community. By combining Appium's flexible automation capabilities with LambdaTest's powerful real device cloud, users gain the ability to test native, hybrid, and web apps on actual hardware, ensuring 100% accuracy. LambdaTest's real device testing environment captures true device behaviour, performance, and user interactions, offering detailed insights through app logs, crash reports, video recordings, and network data. Built specifically for Appium automation at scale, LambdaTest's infrastructure supports high-performance parallel testing, allowing faster release cycles and greater test coverage. Teams can simulate various network conditions and offline modes to assess real-world performance, while geolocation testing enables validation of app behaviour in over 170 countries. "Appium is a cornerstone of modern mobile test automation, and we're proud to be their strategic partner," says Asad Khan, CEO & Co-Founder at LambdaTest. "Our platform empowers testers to execute faster, more secure, and globally distributed Appium tests, turning quality engineering into a competitive advantage." About LambdaTest LambdaTest is an AI-native, omnichannel software quality platform that empowers businesses to accelerate time to market through intelligent, cloud-based test authoring, orchestration, and execution. With over 15,000 customers and 2.3 million+ users across 130+ countries, LambdaTest is the trusted choice for modern software testing. Browser & App Testing Cloud: Enables manual and automated testing of web and mobile apps across 10,000+ browsers, real devices, and OS environments, ensuring cross-platform consistency. HyperExecute: An AI-native test execution and orchestration cloud that runs tests up to 70% faster than traditional grids, offering smart test distribution, automatic retries, real-time logs, and seamless CI/CD integration. KaneAI: The world's first GenAI-native testing agent, leveraging LLMs for effortless test creation, intelligent automation, and self-evolving test execution. It integrates directly with Jira, Slack, GitHub, and other DevOps tools. For more information, please visit View source version on Contacts press@
